> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pfizer/BioNTech on ‘Encouraging’ Covid Booster Data
- URL: https://www.fdaweb.com/pfizer-biontech-on-encouraging-covid-booster-data/
- Published: 2022-11-18T12:00:00.000Z
- Updated: 2026-09-14T18:07:02.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153232

Pfizer and BioNTech have announced results showing that their current authorized bivalent booster vaccine provides a greater increase in neutralizing antibody titers than their original Covid-19 vaccine against emerging Omicron sublineages. “Based on these findings, the Omicron BA.4/BA.5-adapted bivalent booster may help to provide improved protection against Covid-19 due to Omicron BA.4 and BA.5 sublineages as well as new sublineages that continue to increase in prevalence,” the [companies say](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-report-new-data-omicron-ba4ba5-adapted?ref=fdaweb.com).

They say that the latest results are similar to recent clinical [data](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-clinical-data-omicron?ref=fdaweb.com) showing the Omicron BA.4/BA.5-adapted bivalent booster vaccine provides a “13-fold increase in BA.4/BA.5 neutralizing titers from pre-booster levels in individuals 55 years and older, resulting in a 4-fold higher BA.4/BA.5-response than the companies’ original Covid-19 vaccine.”